Search Within

Sarat Chandarlapaty

Formats
  1. Meeting Abstract (143)
  2. Journal Article (128)
  3. Review (9)
  4. Editorial (3)
  5. Guidelines (2)
  6. Book Section (1)
  7. Research Letter (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (287)
  2. Breast Medicine Service (287)
  3. Department of Medicine (287)
  4. GSK Faculty (287)
  5. Human Oncology and Pathogenesis Program (287)
  6. Solid Tumor Oncology Division (287)

More Groups

People
  1. Pedram Razavi (79)
  2. Jorge Reis-Filho (65)
  3. Neal Rosen (58)
  4. Shanu Modi (51)
  5. Jose Baselga (48)
  6. Britta Weigelt (43)

More People

Years
  1. 2025 (17)
  2. 2024 (30)
  3. 2023 (17)
  4. 2022 (25)
  5. 2021 (23)
  6. 2020 (33)

More Years

Publications
  1. Cancer Research (65)
  2. Journal of Clinical Oncology (53)
  3. Annals of Oncology (21)
  4. Cancer Discovery (11)
  5. Clinical Cancer Research (11)
  6. Laboratory Investigation (11)

More Publications

Publishers
  1. American Association for Cancer Research (90)
  2. American Society of Clinical Oncology (57)
  3. Nature Publishing Group (38)
  4. Oxford University Press (24)
  5. Cell Press (14)
  6. Elsevier Inc. (11)

More Publishers

Results (287)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Molecular predictors for type of recurrence following conservative treatment for DCIS
    Meeting Abstract

    Sakr, R. A.; Andrade, V. P.; Chandarlapaty, S.; Giovanni, C.; Giri, D.; Heguy, A.; De Brot, M.; Olvera, N.; Muhsen, S.; Koslow, S.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Datko, F.; D'Andrea, G.; Dickler, M.; Theodoulou, M.; Goldfarb, S.; Lake, D.; Fornier, M.; Modi, S.; Sklarin, N.; Comen, E.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • BAY80-6946 is a potent and selective PI3K inhibitor that induces apoptosis in breast cancers by blocking AKT and non-AKT PI3K effector pathways
    Meeting Abstract

    Will, M.; Toy, W.; Patel, P.; Rodrik-Outmezguine, V.; Schneider, C.; Paul, J.; Liu, N.; Rosen, N.; Chandarlapaty, S.
    European Journal of Cancer (2012)

    Fulltext@MSK | Save
  • A mechanistic logic for dual targeting of HER2 and PI3K/AKT/mTOR signaling in HER2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Rodrik-Outmezguine, V.; Scaltriti, M. M.; Sakr, R.; Will, M.; Giri, D.; Hudis, C.; Baselga, J.; King, T.; Rosen, N.
    European Journal of Cancer (2012)

    Fulltext@MSK | Save
  • Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer
    Journal Article

    Chandarlapaty, S.; Sakr, R. A.; Giri, D.; Patil, S.; Heguy, A.; Morrow, M.; Modi, S.; Norton, L.; Rosen, N.; Hudis, C.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
    Journal Article

    Lito, P.; Pratilas, C. A.; Joseph, E. W.; Tadi, M.; Halilovic, E.; Zubrowski, M.; Huang, A.; Wong, W. L.; Callahan, M. K.; Merghoub, T.; more...
    Cancer Cell (2012)

    Fulltext@MSK | Save
  • Negative feedback and adaptive resistance to the targeted therapy of cancer
    Journal Article

    Chandarlapaty, S.
    Cancer Discovery (2012)

    Fulltext@MSK | Save
  • A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors
    Meeting Abstract

    Han, H. S.; Swanton, C.; Janjigian, Y. Y.; Sutherland, S. C.; Chandarlapaty, S.; Lehman, R.; Hamilton, N.; Knowles, J.; Lee, R.; Yan, L.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer
    Meeting Abstract

    Gajria, D.; King, T. A.; Pannu, H.; Sakr, R.; Seidman, A. D.; Syldor, A.; Patil, S.; Maybody, M.; Norton, L.; Rosen, N.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save